3. Bates ME, Bowden SC, Barry D. Neurocognitive impairment
associated with alcohol use disorders: implications for treatment. Exp
Clin Psychopharmacol. 2002;10:193-212.
4. Volkow ND, Mullani N, Gould KL, Adler S, Krajewski K. Cerebral
blood flow in chronic cocaine users: a study with positron emission
tomography. Br J Psychiatry. 1988;152:641-648.
5. Filley CM, Halliday W, Kleinschmidt-DeMasters BK. The effects of
toluene on the central nervous system. J Neuropathol Exp Neurol.
2004;63:1-12.
6. Phelps ME, Mazziotta JC. Positron emission tomography: human
brain function and biochemistry. Science. 1985;228:799-809.
7. Reivich M, Kuhl D, Wolf A, et al. The [18F]fluorodeoxyglucose
method for the measurement of local cerebral glucose utilization in
man. Circ Res. 1979;44:127-137.
8. Volkow ND, Fowler JS, Gatley SJ, et al. PET evaluation of the
dopamine system of the human brain. J Nucl Med. 1996;37:1242-1256.
9. Volkow ND, Ding YS, Fowler JS, Gatley SJ. Imaging brain
cholinergic activity with positron emission tomography: its role in the
evaluation of cholinergic treatments in Alzheimer's dementia. Biol
Psychiatry. 2001;49:211-220.
10. Brooks DJ. Neuroimaging in Parkinson's disease. NeuroRx.
2004;1:243-254.
11. Kircher TT, Thienel R. Functional brain imaging of symptoms and
cognition in schizophrenia. Prog Brain Res. 2005;150:299-308.
12. Smith GS, Koppel J, Goldberg S. Applications of neuroreceptor
imaging to psychiatry research. Psychopharmacol Bull.
2003;37:26-65.
13. Gatley SJ, Volkow ND, Wang GJ, et al. PET imaging in clinical
drug abuse research. Curr Pharm Des. 2005;11:3203-3219.
14. Kumar R, Nadig MR, Chauhan A. Positron emission tomography:
clinical applications in oncology. Part 1. Expert Rev Anticancer Ther.
2005;5:1079-1094.
15. Alexoff DL, Vaska P, Marsteller D, et al. Reproducibility of 11Craclopride binding in the rat brain measured with the microPET R4:
effects of scatter correction and tracer specific activity. J Nucl Med.
2003;44:815-822.
16. Knoess C, Siegel S, Smith A, et al. Performance evaluation of the
microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging.
2003;30:737-747.
17. Fahey FH, Gage HD, Buchheimer N, et al. Evaluation of the
quantitative capability of a high-resolution positron emission
tomography scanner for small animal imaging. J Comput Assist Tomogr.
2004;28:842-848.
18. Brownell AL, Chen YI, Yu M, et al. 3-Nitropropionic acid-induced
neurotoxicity–assessed by ultra high resolution positron emission
tomography with comparison to magnetic resonance spectroscopy.
J Neurochem. 2004;89:1206-1214.
19. Curtis HJ. The biological effects of heavy cosmic ray particles.
Life Sci Space Res. 1963;1:39-47.
20. Joseph JA, Hunt WA, Rabin BM, Dalton TK. Possible “accelerated
striatal aging” induced by 56Fe heavy-particle irradiation: implications
for manned space flights. Radiat Res. 1992;130:88-93.
21. Curtis SB, Vazquez ME, Wilson JW, Atwell W, Kim M, Capala J.
Cosmic ray hit frequencies in critical sites in the central nervous system.
Adv Space Res. 1998;22:197-207.
22. Hunt WA, Dalton TK, Joseph JA, Rabin BM. Reduction of
3-methoxytyramine concentrations in the caudate nucleus of rats after
exposure to high-energy iron particles:evidence for deficits in
dopaminergic neurons. Radiat Res. 1990;121:169-174.
